#NexeraPharmaInc

Lilly acquires the OX2 agonist series from Nexera Pharma’s partner Centessa. Nexera Pharma retains milestone and royalty rights and expects mid- to long-term business profit growth.

Nexera Pharma Inc. received $1.8 million (approximately JPY 281 million) as a milestone payment from Centessa for the development drug targeting neuropsychiatric disorders, scheduled to be recorded as revenue in the first quarter of the fiscal year ending December 2026.